Brief: Citius Pharmaceuticals Announces Addition Of City Of Hope To UMN's Phase 1 Trial Of LYMPHIR
11/04/2024 15:29
April 11 (Reuters) - Citius Pharmaceuticals Inc
CTXR.O :
* CITIUS PHARMACEUTICALS ANNOUNCES ADDITION OF CITY OF HOPE
TO
UMN'S PHASE 1 TRIAL OF LYMPHIR IN COMBINATION WITH CAR-T FOR THE
TREATMENT OF B-CELL LYMPHOMA
Source text for Eikon: ID:nPn7q9LSra
Further company coverage: CTXR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Citius Pharmaceuticals
See all newsCitius Pharmaceuticals Q2 revenue rises on LYMPHIR launch
Citius Pharmaceuticals reports first revenue of $3.9 mln
Brief: Citius Oncology Expands International Distribution Of Lymphir™ To European Union Through Exclusive Agreement With Uniphar
Brief: Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results And Provides Business Update
Brief: Citius Oncology Announces $18 Million Concurrent Registered Direct Offering And Private Placement Priced At-The-Market Under Nasdaq Rules